^
    3d
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (clinicaltrials.gov)
    P2, N=25, Recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
    8d
    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=705, Recruiting, Zenas BioPharma (USA), LLC | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Inokai (orelabrutinib)
    10d
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Peking University Third Hospital
    New trial
    |
    Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
    17d
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (clinicaltrials.gov)
    P2, N=79, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Jun 2025 --> Dec 2025
    Trial initiation date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)
    17d
    Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    1m
    Clinical Study on the Efficacy and Safety of Orelabrutinib Consolidation and Maintenance Therapy in Patients with Previously Untreated Marginal Zone Lymphoma (ChiCTR2500110878)
    P2, N=23, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    2ms
    Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL (clinicaltrials.gov)
    P2, N=169, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib) • bendamustine
    2ms
    ADAPT-MCL: Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Inokai (orelabrutinib) • bendamustine
    2ms
    Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Zhengzhou University
    New trial
    |
    Tyvyt (sintilimab) • Inokai (orelabrutinib) • Carteyva (relmacabtagene autoleucel)
    2ms
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment (clinicaltrials.gov)
    P2, N=45, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • cytarabine • etoposide IV • Inokai (orelabrutinib) • carmustine • melphalan
    3ms
    A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, Ruijin Hospital
    New trial
    |
    temozolomide • Xpovio (selinexor) • Inokai (orelabrutinib) • thiotepa
    3ms
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (clinicaltrials.gov)
    P2/3, N=215, Not yet recruiting, Huashan Hospital
    New P2/3 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • dexamethasone • Vumon (teniposide)